Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 7 | 2022 | 283 | 2.560 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 37 | 0.950 |
Why?
|
| Lung Diseases | 2 | 2022 | 175 | 0.870 |
Why?
|
| Bronchiectasis | 1 | 2021 | 25 | 0.760 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 83 | 0.760 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 26 | 0.710 |
Why?
|
| Patient Care Management | 1 | 2020 | 40 | 0.700 |
Why?
|
| Hemoptysis | 1 | 2019 | 28 | 0.680 |
Why?
|
| Pneumothorax | 1 | 2019 | 42 | 0.680 |
Why?
|
| Rural Health Services | 1 | 2020 | 101 | 0.660 |
Why?
|
| Burkholderia cepacia complex | 1 | 2018 | 2 | 0.620 |
Why?
|
| Burkholderia Infections | 1 | 2018 | 4 | 0.620 |
Why?
|
| Pneumonia, Bacterial | 1 | 2018 | 19 | 0.610 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 3 | 0.610 |
Why?
|
| Ribavirin | 1 | 2017 | 27 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 1026 | 0.560 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 232 | 0.560 |
Why?
|
| Lung Transplantation | 1 | 2017 | 88 | 0.550 |
Why?
|
| Antiviral Agents | 1 | 2017 | 211 | 0.510 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.510 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.400 |
Why?
|
| Lung | 3 | 2022 | 849 | 0.400 |
Why?
|
| Postoperative Complications | 2 | 2022 | 1615 | 0.380 |
Why?
|
| Glucosamine | 2 | 2022 | 8 | 0.370 |
Why?
|
| Administration, Oral | 2 | 2018 | 411 | 0.280 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.270 |
Why?
|
| Nontuberculous Mycobacteria | 2 | 2022 | 22 | 0.250 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.230 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2022 | 11 | 0.200 |
Why?
|
| Mycobacterium avium Complex | 1 | 2022 | 16 | 0.200 |
Why?
|
| Humans | 11 | 2022 | 68618 | 0.200 |
Why?
|
| Pneumonia | 1 | 2022 | 110 | 0.200 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 6 | 0.200 |
Why?
|
| Biofilms | 1 | 2022 | 72 | 0.190 |
Why?
|
| Pregnancy Rate | 1 | 2021 | 14 | 0.190 |
Why?
|
| Chloride Channel Agonists | 1 | 2021 | 6 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 26 | 0.190 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 133 | 0.190 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 25 | 0.180 |
Why?
|
| Mucin-5B | 1 | 2019 | 1 | 0.170 |
Why?
|
| Mucociliary Clearance | 1 | 2019 | 21 | 0.170 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 149 | 0.170 |
Why?
|
| Mucus | 1 | 2019 | 33 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 5 | 0.160 |
Why?
|
| Ceftazidime | 1 | 2018 | 12 | 0.160 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2018 | 22 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2022 | 7029 | 0.150 |
Why?
|
| Azithromycin | 1 | 2018 | 13 | 0.150 |
Why?
|
| Tobramycin | 1 | 2018 | 38 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 89 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 39 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 187 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2018 | 172 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 955 | 0.140 |
Why?
|
| Polymers | 1 | 2019 | 244 | 0.140 |
Why?
|
| Rural Population | 1 | 2020 | 398 | 0.140 |
Why?
|
| Rats | 2 | 2022 | 5300 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 649 | 0.130 |
Why?
|
| Adult | 5 | 2022 | 21403 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2279 | 0.120 |
Why?
|
| South Carolina | 1 | 2020 | 2752 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2324 | 0.100 |
Why?
|
| Middle Aged | 2 | 2018 | 21147 | 0.090 |
Why?
|
| Female | 3 | 2021 | 38074 | 0.070 |
Why?
|
| Animals | 2 | 2022 | 20881 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 5717 | 0.070 |
Why?
|
| Male | 2 | 2018 | 37321 | 0.070 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.050 |
Why?
|
| Colectomy | 1 | 2022 | 64 | 0.050 |
Why?
|
| Aged | 1 | 2017 | 14862 | 0.050 |
Why?
|
| Aminophenols | 1 | 2021 | 19 | 0.050 |
Why?
|
| Benzodioxoles | 1 | 2021 | 30 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2021 | 45 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2022 | 382 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 371 | 0.050 |
Why?
|
| Quinolones | 1 | 2021 | 60 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 304 | 0.040 |
Why?
|
| Indoles | 1 | 2021 | 146 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 190 | 0.040 |
Why?
|
| Mice, Inbred CFTR | 1 | 2019 | 1 | 0.040 |
Why?
|
| Ferrets | 1 | 2019 | 3 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2019 | 31 | 0.040 |
Why?
|
| Viscosity | 1 | 2019 | 72 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 52 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2019 | 51 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 261 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 780 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2077 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2334 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 8912 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 8474 | 0.020 |
Why?
|